A Study To Assess GW433908 (Fosamprenavir) Containing Regimens In HIV-1 Infected Subjects
Status:
Completed
Trial end date:
2010-10-01
Target enrollment:
Participant gender:
Summary
GW433908 (fosamprenavir; FPV)is a pro-drug of amprenavir (APV) which is more water soluble
and can be formulated into a tablet with a reduced pill burden (four 700mg tablets of FPV
versus sixteen 150mg capsules daily for APV. This study is designed to provide additional
information on long term safety and tolerability of FPV containing regimens for those
subjects who received FPV in previous GlaxoSmithKline studies.